Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study

被引:27
作者
Barrat, Emmanuel [1 ]
Zair, Yassine [2 ]
Sirvent, Pascal [3 ]
Chauveau, Patrice [4 ]
Maudet, Corinne [4 ]
Housez, Beatrice [4 ]
Derbord, Elodie [1 ]
Lescuyer, Jean-Francois [1 ]
Bard, Jean-Marie [5 ,6 ]
Cazaubiel, Murielle [4 ]
Peltier, Sebastien L. [1 ]
机构
[1] Lab Lescuyer, Dept Res, F-17442 Aytre, France
[2] Nantes Univ Hosp, Dept Endocrinol, Inst Thorax, F-44007 Nantes 1, France
[3] Univ Blaise Pascal, Clermont Univ, Lab Adaptat Metabol Exercice Condit Physiol & Pat, EA 3533, F-63000 Clermont Ferrand, France
[4] Biofortis Merieux Nutrisci Co, F-44800 St Herblain, France
[5] LUNAM, Nantes EA2160, F-44800 St Herblain, France
[6] Inst Cancerol Ouest, F-44800 St Herblain, France
关键词
Red yeast rice; Policosanols; Artichoke leaf extract; Muscle breakdown; Withdrawal; SKELETAL-MUSCLE; EFFICACY; POLICOSANOL; SAFETY; RICE; TOLERABILITY; IMPAIRMENT; MANAGEMENT; INCREASES;
D O I
10.1007/s00394-012-0486-2
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
To determine the effect of 4 weeks of supplementation, then, withdrawal of a dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract at twice the recommended daily dose (6 tablets, 6-TAB) compared to the usual dose (3-TAB) or to a placebo (PLA), on blood lipid profiles and safety biomarkers. Forty-five healthy subjects (15 per group), with untreated hypercholesterolaemia, were included in this randomised, double-blind, placebo-controlled clinical trial. After 4 weeks of supplementation, LDL-C was significantly lower in 6-TAB (-0.21 g/l; 95 % CI -0.38 to -0.03 g/l; p = 0.0217) and 3-TAB (-0.25 g/l; 95 % CI -0.42 to -0.07 g/l; p = 0.0071) compared to PLA, although no difference in LDL-cholesterol was observed between the two groups, while no effect was seen on triacylglycerol and HDL-cholesterol. Four weeks after the end of supplementation, no difference in LDL-C was seen between the PLA group and the DS-treated groups. The muscle breakdown biomarkers, as well as biomarkers of liver and renal function, were altered by neither dose of the DS. Acute application of the DS on permeabilised skeletal muscle fibres of rats did not induce deleterious effects on mitochondrial function. Supplementation with twice the recommended dose of the DS was effective in reducing LDL-cholesterol and appeared safe, but according to the present results, no additional benefit could be achieved compared to the recommended dose.
引用
收藏
页码:1843 / 1852
页数:10
相关论文
共 29 条
  • [1] Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia - A randomized controlled trial
    Berthold, HK
    Unverdorben, S
    Degenhardt, R
    Bulitta, M
    Gouni-Berthold, I
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19): : 2262 - 2269
  • [2] Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress
    Bouitbir, Jamal
    Charles, Anne-Laure
    Rasseneur, Laurence
    Dufour, Stephane
    Piquard, Francois
    Geny, Bernard
    Zoll, Joffrey
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 2011, 111 (05) : 1477 - 1483
  • [3] Castaño G, 2002, INT J CLIN PHARM RES, V22, P55
  • [4] Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: A dose-response effect dependent on endothelial nitric oxide synthase
    Chen, Hong
    Ren, Jing-Yi
    Xing, Yan
    Zhang, Wan-Lei
    Liu, Xin
    Wu, Pei
    Wang, Ruo-Jie
    Luo, Yu
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 131 (03) : 313 - 320
  • [5] Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia
    Crouse, JR
    Lukacsko, P
    Niecestro, R
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) : 226 - +
  • [6] Englisch W, 2000, ARZNEIMITTELFORSCH, V50, pE260
  • [7] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [8] Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent
    Gouni-Berthold, I
    Berthold, HK
    [J]. AMERICAN HEART JOURNAL, 2002, 143 (02) : 356 - 365
  • [9] Heber D, 1999, AM J CLIN NUTR, V69, P231
  • [10] EFFICACY AND SAFETY OF PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA .1. A DOSE-RESPONSE STUDY
    HUNNINGHAKE, DB
    KNOPP, RH
    SCHONFELD, G
    GOLDBERG, AC
    BROWN, WV
    SCHAEFER, EJ
    MARGOLIS, S
    DOBS, AS
    MELLIES, MJ
    INSULL, W
    STEIN, EA
    [J]. ATHEROSCLEROSIS, 1990, 85 (01) : 81 - 89